Open AccessSecondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report
Author(s) -
Masood Adeel,
Wahab Ahsan,
Clifford Tanya,
Weaver Eric J.,
Ehsan Hamid,
El Ayass Walid
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5184
Subject(s) - medicine , nivolumab , ipilimumab , hemophagocytic lymphohistiocytosis , discontinuation , complication , immunotherapy , cancer , pediatrics , oncology , disease
Secondary immune‐related hemophagocytic lymphohistiocytosis is a rare but life‐threatening complication of immune checkpoint inhibitors. HLH‐2004 and HLH‐1994 guidelines originally developed for primary HLH are the only available guidelines. It has proven to have a good prognosis if diagnosed promptly with discontinuation of immunotherapy and treated with corticosteroid monotherapy.